Nurix Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Piper Sandler & Co., and Stifel, Nicolaus & Company, Incorporated to issue and sell shares of its common stock and pre-funded warrants to the underwriters, with estimated net proceeds of approximately $164.0 million to be used for clinical development, research and development, and general corporate purposes.